Zenith Study: Efficacy of Tezepelumab in Peanut Oral Immunotherapy; A Double-Blind, Randomized, Placebo-Controlled Trial

Sep 16, 2026

Study Description

The ZENITH Study is evaluating whether peanut oral immunotherapy (OIT) used in combination with an investigational medication, called tezepelumab, will help people with peanut allergy become less sensitive to peanuts and lower the risk of life threatening allergic reactions.

Study Eligibility

You may be eligible to participate if you:

Are between the ages of 12 and 34
Have a peanut allergy

What to Expect

Peanut allergic study participants between the ages of 12 and 34 will be randomly assigned to one of two groups. Initially, one group will receive tezepelumab and the other will receive a placebo. After 8 weeks, peanut oral immunotherapy (OIT) will be added to each group for a period of 56 weeks. Then, participants will stop taking both tezepelumab/placebo and OIT for 12 weeks.

Compensation for time and travel may be available.